eClinicalソリューション市場：臨床試験フェーズ別、製品別（CDMS、EDC、CTMS、eCOA、RTSM、ETMF、分析、統合、安全性）、提供形態別（Webベース、オンデマンド、オンプレミス、クラウド）、エンドユーザー別（製薬・バイオ、病院、CRO） - 2026年までの世界予測

eClinical Solutions Market by Clinical trial phases, Product (CDMS, EDC, CTMS, eCOA, RTSM, ETMF, Analytics, Integration, Safety), Delivery (Web-based, On demand, On premise, Cloud), End user (Pharma & Biotech, Hospitals, CROs) - Global Forecasts to 2026

eクリニカルソリューションの世界市場は、2021年の83億米ドルから2026年までに154億米ドルに達すると予測されており、年平均成長率は13.3%となっています。臨床研究に関連する運用コストや規制要件の増加、臨床試... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2021年9月16日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	225	266	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

eクリニカルソリューションの世界市場は、2021年の83億米ドルから2026年までに154億米ドルに達すると予測されており、年平均成長率は13.3%となっています。臨床研究に関連する運用コストや規制要件の増加、臨床試験を支援するための政府助成金、製薬・バイオテクノロジー企業による医薬品開発のための研究開発費の増加などが、世界のeClinicalソリューション市場の主な推進要因となっています。
クラウドベース（SaaS）セグメントが最も高いCAGRを記録すると予測される
世界のeClinicalソリューション市場は、提供形態に基づいて、ウェブホスト型（オンデマンド）、ライセンス型企業（オンプレミス）、クラウドベース（SaaS）のソリューションに分類されます。2020年には、ウェブホスティング（オンデマンド）セグメントが世界のeClinicalソリューション市場で最大のシェアを占めました。クラウドベースの臨床試験ソリューションの数が増加していることと、臨床研究におけるこれらのソリューションの採用が増えていること（統合が容易で、迅速な展開が可能で、固定の月額料金で柔軟な拡張性が得られるなどの利点があるため）が、クラウドベースのeClinicalソリューション市場の成長を促進しています。

予測期間中、第3相臨床試験が最も高い成長を示すと予想される
臨床試験のフェーズに基づいて、eClinicalソリューション市場は第I相試験、第II相試験、第III相試験、第IV相試験に分類されています。2020年のeClinicalソリューション市場では、第III相臨床試験のセグメントが最大のシェアを占めています。このセグメントの大きなシェアは、第III相臨床試験では数千人の患者が関与するため、eClinicalソリューションの需要が高いことに起因しています。

CROセグメントは、予測期間中に最も高いCAGRを記録すると推定されます。
エンドユーザー別に見ると、世界のeClinicalソリューション市場は、製薬・バイオ製薬企業、医薬品開発業務受託機関、コンサルティングサービス企業、医療機器メーカー、病院、学術研究機関に分類されます。2020年のeClinicalソリューション市場では、製薬会社・バイオ製薬会社セグメントが最大のシェアを占めています。しかし、CROセグメントは、今後5年間で最も高いCAGR（15.5％）を記録すると予測されます。先進国だけでなく発展途上国でもCROの数が増えていることや、専門の臨床研究機関に臨床試験を委託する事例が増えていることが、このセグメントの高い成長率の原因となっています。

北米は2021年から2026年にかけて大きな成長を遂げる
この地域では、臨床試験を支援する政府補助金の増加、eClinicalソリューションベンダーによる継続的な製品開発と新製品の発売、新薬開発のための提携数の増加などが、eClinicalソリューションの需要をさらに刺激しています。

供給側一次インタビューの内訳- 企業タイプ別。企業タイプ別：Tier1 - 33%、Tier2 - 42%、Tier3 - 18% - 意欲別。Cレベル - 29%, ディレクターレベル - 23%, その他 - 48% - 地域別。北米 - 35%、欧州 - 30%、APAC - 26%、その他の地域 - 9
この市場の著名な企業としては、オラクルコーポレーション（米国）、メディデータ・ソリューションズ Inc.(米国)、Parexel International Corporation (米国)、BioClinica, Inc.(米国)、Signant Health (米国)、Datatrak International, Inc.(米国)、ERT(米国)、eClinical Solutions, Inc.(米国)、MaxisIT Inc.(米国)、Bio-Optronics, Inc.(米国)、Merge Healthcare Incorporated(米国)、OmniComm Systems, Inc.(米国)

調査範囲
本レポートでは、製品、提供形態、臨床試験のフェーズ、エンドユーザー、地域に基づいて、eClinical Solutions市場を説明・調査しています。この市場の成長に影響を与える主な要因と、市場力学に影響を与える要因に関する詳細な情報を提供しています。本レポートには、この市場における著名な企業の詳細な競合分析と製品マトリックスが含まれており、企業プロフィール、製品ポートフォリオ、最近の開発状況（合併、買収、パートナーシップ、協力関係など）、主要な事業戦略などが記載されています。

このレポートを購入する主なメリット
本レポートでは、様々なレベルの分析-業界動向、トッププレイヤーの市場シェア、企業プロファイルに焦点を当て、これらを合わせて基本的な見解を形成し、競合環境、高成長地域とそのドライバー、抑制、課題、機会を分析しています。本レポートは、既存の企業だけでなく、新規参入者や小規模な企業が市場の動向を把握し、より大きなシェアを獲得するために役立ちます。

ページTOPに戻る

Table of Contents

Summary

The global eClinical Solutions market is projected to reach USD 15.4 billionby 2026 from USD 8.3 billion in 2021 at a CAGR of 13.3%. Increasing operational costs and regulatory requirements associated with clinical research studies, government grants to support clinical trials, and growing R&D expenditure on drug development by pharma-biotech companies are some of the major driving factors for the global eClinical solutions market.
Cloud-based (SaaS) segment is projected to record the highest CAGR
Based on delivery mode, the global eClinical solutions market is segmented into web-hosted (on-demand), licensed enterprise (on-premises), and cloud-based (SaaS) solutions. In 2020, the web-hosted (on-demand) segment commanded the largest share of the global eClinical solutions market. The increasing number of cloud-based clinical trial solutions in the market and the rising adoption of these solutions in clinical research studies (owing to advantages such as ease of integration, quicker deployment, and flexible scalability with a fixed monthly fee) are fueling the growth of the cloud-based eClinical solutions market.

Phase III clinical trials is expected to register the highest growth during the forecast period
Based on clinical trial phase, the eClinical solutions market has been segmented into phase I, phase II, phase III, and phase IV trials. The phase III clinical trials segment accounted for the largest share of the eClinical solutions market in 2020. The large share of this segment is attributed to the high demand for eClinical solutions for phase III trials due to the involvement of thousands of patients in this phase.

CROs segment is estimated to record the highest CAGR in the forecast period.
Based on end user, the global eClinical solutions market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, consulting service companies, medical device manufacturers, hospitals, and academic research institutions. The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the eClinical solutions market in 2020. However, the CROs segment is estimated to record the highest CAGR (15.5%) in the next five years. The increasing number of CROs in developed as well as developing countries, and the rising instances of clinical trial outsourcing to specialized clinical research organizations are responsible for the high growth rate of this segment.

North America To Witness Significant Growth From 2021 To 2026
In 2020, North America commanded the largest share of the eClinical solutions market.Increasing government grants to support clinical trials, continuous product development and new product launches by eClinical solution vendors, and growth in the number of partnerships for new drug development are further stimulating the demand for eClinical solutions in this region.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 33%, Tier 2 – 42%, and Tier 3 – 18% • By Designation: C-level – 29%, Director-level – 23%, and Others – 48% • By Region: North America - 35%, Europe – 30%, APAC –26%, Rest of the World –9%
Some of the prominent players in this market are Oracle Corporation (US), Medidata Solutions, Inc. (US), Parexel International Corporation (US), BioClinica, Inc. (US), Signant Health (US), Datatrak International, Inc. (US), ERT (US), eClinical Solutions, Inc. (US), MaxisIT Inc. (US), Bio-Optronics, Inc. (US), Merge Healthcare Incorporated (US), and OmniComm Systems, Inc. (US)

Research Coverage
This report describes and studies the eClinical Solutions market based on product, delivery mode, clinical trials phases, end users and region. It provides detailed information regarding the major factors influencing the growth of this market and the factors impacting market dynamics. The report includes in-depth competitive analysis and the product matrix of the prominent players in this market, along with their company profiles, product portfolios, recent developments (mergers, acquisitions, partnerships, collaborations, etc.), and key business strategies.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

ページTOPに戻る

1 INTRODUCTION 33

1.1 OBJECTIVES OF THE STUDY 33

1.2 MARKET DEFINITION 33

1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 34

1.2.2 MARKETS COVERED 35

1.2.3 GEOGRAPHIC SCOPE 35

1.2.4 YEARS CONSIDERED FOR THE STUDY 36

1.3 CURRENCY 36

1.4 LIMITATIONS 36

1.5 MAJOR MARKET STAKEHOLDERS 37

1.6 SUMMARY OF CHANGES 37

2 RESEARCH METHODOLOGY 38

2.1 RESEARCH APPROACH 38

2.2 RESEARCH METHODOLOGY DESIGN 38

FIGURE 1 ECLINICAL SOLUTIONS MARKET: RESEARCH DESIGN 38

2.2.1 SECONDARY RESEARCH 39

2.2.1.1 Key data from secondary sources 39

2.2.2 PRIMARY DATA 40

FIGURE 2 PRIMARY SOURCES 40

2.2.2.1 Key data from primary sources 41

2.2.2.2 Insights from primary experts 42

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS:

BY COMPANY, DESIGNATION, AND REGION 43

2.3 MARKET SIZE ESTIMATION: ECLINICAL SOLUTIONS MARKET 43

FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44

FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION 44

FIGURE 6 REVENUE ANALYSIS OF TOP 3 PUBLIC COMPANIES:

ECLINICAL SOLUTIONS MARKET (2020) 45

FIGURE 7 BOTTOM-UP APPROACH 46

FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ECLINICAL

SOLUTIONS MARKET (2021–2026) 47

FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 48

FIGURE 10 TOP-DOWN APPROACH 48

2.4 MARKET BREAKDOWN & DATA TRIANGULATION 49

FIGURE 11 DATA TRIANGULATION METHODOLOGY 49

2.5 MARKET SHARE ESTIMATION 50

2.6 ASSUMPTIONS FOR THE STUDY 50

2.7 LIMITATIONS 50

2.7.1 METHODOLOGY-RELATED LIMITATIONS 50

2.7.2 SCOPE-RELATED LIMITATIONS 51

2.8 RISK ASSESSMENT 51

TABLE 1 RISK ASSESSMENT: ECLINICAL SOLUTIONS MARKET 51

3 EXECUTIVE SUMMARY 52

FIGURE 12 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2021 VS. 2026 (USD MILLION) 53

FIGURE 13 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2021 VS. 2026 (USD MILLION) 54

FIGURE 14 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2021 VS. 2026 (USD MILLION) 54

FIGURE 15 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2021 VS. 2026 (USD MILLION) 55

FIGURE 16 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2020 (USD MILLION) 56

4 PREMIUM INSIGHTS 57

4.1 ECLINICAL SOLUTIONS: MARKET OVERVIEW 57

FIGURE 17 EMERGING COUNTRIES OFFER HIGH GROWTH OPPORTUNITIES DURING FORECAST PERIOD 57

4.2 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET,

BY DELIVERY MODE AND COUNTRY (2020) 58

FIGURE 18 WEB-HOSTED DELIVERY MODE DOMINATED ECLINICAL

SOLUTIONS MARKET IN 2020 58

4.3 ECLINICAL SOLUTIONS MARKET SHARE, BY CLINICAL TRIAL PHASE (2021 VS. 2026) 58

FIGURE 19 PHASE III CLINICAL TRIALS TO DOMINATE GLOBAL ECLINICAL SOLUTIONS MARKET DURING FORECAST PERIOD 58

5 MARKET OVERVIEW 59

5.1 INTRODUCTION 59

5.2 MARKET DYNAMICS 59

FIGURE 20 GLOBAL ECLINICAL SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59

5.2.1 MAJOR MARKET DRIVERS 60

5.2.1.1 Increasing operational costs and regulatory requirements associated with clinical research studies 60

5.2.1.2 Growing adoption of novel software solutions in clinical research 60

5.2.1.3 Increased government funding and grants to support clinical trials 61

5.2.1.4 Need for improved data standardization 61

5.2.1.5 Increasing R&D expenditure on drug development pipeline by pharma-biotech companies 62

5.2.1.6 Growing customer base for eClinical solutions 62

TABLE 2 US: INDICATIVE LIST OF LIFE SCIENCE STARTUPS LAUNCHED

BETWEEN 2011 & 2015 63

5.2.2 MAJOR MARKET RESTRAINTS 63

5.2.2.1 High implementation costs associated with eClinical solutions 63

5.2.2.2 Dearth of skilled professionals to operate eClinical solutions 63

5.2.2.3 Limited awareness of advantages of eClinical solutions among researchers 64

5.2.3 KEY GROWTH OPPORTUNITIES 64

5.2.3.1 Increasing clinical research activities in emerging Asian countries 64

5.2.3.2 Greater outsourcing of clinical trial processes to CROs 64

5.2.3.3 Rising number of clinical trials in emerging countries 64

5.2.3.4 Shift from manual data interpretation to real-time data analysis during clinical studies 65

5.2.4 MAJOR MARKET CHALLENGES 65

5.2.4.1 Limited adoption of eClinical solutions in developing nations 65

5.2.4.2 Concerns about software reliability 65

5.2.4.3 Patient privacy issues 66

5.3 IMPACT OF COVID-19 ON THE ECLINICAL SOLUTIONS MARKET 66

5.4 ECOSYSTEM ANALYSIS OF ECLINICAL SOLUTIONS MARKET 67

FIGURE 21 ECOSYSTEM ANALYSIS OF ECLINICAL SOLUTIONS MARKET 67

5.5 CASE STUDIES 67

5.5.1 YORK TEACHING HOSPITAL SPEEDS UP DATA CAPTURE PROCESS DURING PHASE III CLINICAL STUDY 67

5.5.2 LSHTM AND MENAFRICAR USE DATA CAPTURE SOFTWARE TO STUDY MENINGOCOCCAL CARRIAGE IN AFRICAN MENINGITIS BELT 67

5.5.3 CLINICAL TRIALS GROUP AT UCL USES EDC SYSTEM TO

CAPTURE AND VERIFY PATIENT FEEDBACK 68

5.6 VALUE CHAIN ANALYSIS 68

FIGURE 22 ECLINICAL SOLUTIONS : VALUE CHAIN 68

5.7 PORTER’S FIVE FORCES ANALYSIS 68

TABLE 3 HIGH CAPITAL INVESTMENTS TO RESTRICT ENTRY OF NEW PLAYERS 68

5.7.1 THREAT OF NEW ENTRANTS 69

5.7.2 THREAT OF SUBSTITUTES 69

5.7.3 BARGAINING POWER OF BUYERS 69

5.7.4 BARGAINING POWER OF SUPPLIERS 69

5.7.5 INTENSITY OF COMPETITIVE RIVALRY 69

6 GLOBAL ECLINICAL SOLUTIONS MARKET, BY PRODUCT 70

6.1 INTRODUCTION 71

TABLE 4 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 71

TABLE 5 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 72

6.2 ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS 72

TABLE 6 GLOBAL ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2015–2018 (USD MILLION) 73

TABLE 7 NORTH AMERICA: ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY,

2015–2018 (USD MILLION) 73

TABLE 8 GLOBAL ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2019–2026 (USD MILLION) 73

TABLE 9 NORTH AMERICA: ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY,

2019–2026 (USD MILLION) 74

6.3 CLINICAL TRIAL MANAGEMENT SYSTEMS 74

TABLE 10 GLOBAL CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2015–2018 (USD MILLION) 75

TABLE 11 NORTH AMERICA: CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE,

BY COUNTRY, 2015–2018 (USD MILLION) 75

TABLE 12 GLOBAL CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2019–2026 (USD MILLION) 75

TABLE 13 NORTH AMERICA: CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE,

BY COUNTRY, 2019–2026 (USD MILLION) 76

6.4 CLINICAL ANALYTICS PLATFORMS 76

TABLE 14 GLOBAL CLINICAL ANALYTICS PLATFORMS MARKET SIZE, BY REGION,

2015–2018 (USD MILLION) 77

TABLE 15 NORTH AMERICA: CLINICAL ANALYTICS PLATFORMS MARKET SIZE,

BY COUNTRY, 2015–2018 (USD MILLION) 77

TABLE 16 GLOBAL CLINICAL ANALYTICS PLATFORMS MARKET SIZE, BY REGION,

2019–2026 (USD MILLION) 77

TABLE 17 NORTH AMERICA: CLINICAL ANALYTICS PLATFORMS MARKET SIZE,

BY COUNTRY, 2019–2026 (USD MILLION) 78

6.5 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT 78

TABLE 18 GLOBAL RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY REGION, 2015–2018 (USD MILLION) 78

TABLE 19 NORTH AMERICA: RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2018 (USD MILLION) 79

TABLE 20 GLOBAL RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY REGION, 2019–2026 (USD MILLION) 79

TABLE 21 NORTH AMERICA: RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2019–2026 (USD MILLION) 79

6.6 CLINICAL DATA INTEGRATION PLATFORMS 79

TABLE 22 GLOBAL CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE,

BY REGION, 2015–2018 (USD MILLION) 80

TABLE 23 NORTH AMERICA: CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE, BY COUNTRY, 2015–2018 (USD MILLION) 80

TABLE 24 GLOBAL CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE,

BY REGION, 2019–2026 (USD MILLION) 81

TABLE 25 NORTH AMERICA: CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE, BY COUNTRY, 2019–2026 (USD MILLION) 81

6.7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS 81

TABLE 26 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY REGION, 2015–2018 (USD MILLION) 82

TABLE 27 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2018 (USD MILLION) 82

TABLE 28 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY REGION, 2019–2026 (USD MILLION) 82

TABLE 29 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2019–2026 (USD MILLION) 83

6.8 SAFETY SOLUTIONS 83

TABLE 30 GLOBAL SAFETY SOLUTIONS MARKET SIZE, BY REGION,

2015–2018 (USD MILLION) 83

TABLE 31 NORTH AMERICA: SAFETY SOLUTIONS MARKET SIZE, BY COUNTRY,

2015–2018 (USD MILLION) 84

TABLE 32 GLOBAL SAFETY SOLUTIONS MARKET SIZE, BY REGION,

2019–2026 (USD MILLION) 84

TABLE 33 NORTH AMERICA: SAFETY SOLUTIONS MARKET SIZE, BY COUNTRY,

2019–2026 (USD MILLION) 84

6.9 ELECTRONIC TRIAL MASTER FILE SYSTEMS 84

TABLE 34 GLOBAL ELECTRONIC TRIAL MASTER FILE SYSTEMS MARKET SIZE,

BY REGION, 2015–2018 (USD MILLION) 85

TABLE 35 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE MARKET SIZE,

BY COUNTRY, 2015–2018 (USD MILLION) 85

TABLE 36 GLOBAL ELECTRONIC TRIAL MASTER FILE SYSTEMS MARKET SIZE,

BY REGION, 2019–2026 (USD MILLION) 85

TABLE 37 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE MARKET SIZE,

BY COUNTRY, 2019–2026 (USD MILLION) 86

6.10 REGULATORY INFORMATION MANAGEMENT SOLUTIONS 86

TABLE 38 GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE, BY REGION, 2015–2018 (USD MILLION) 86

TABLE 39 NORTH AMERICA: GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE ,BY COUNTRY, 2015–2018 (USD MILLION) 87

TABLE 40 GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE, BY REGION, 2019–2026 (USD MILLION) 87

TABLE 41 NORTH AMERICA: GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE, BY COUNTRY, 2019–2026 (USD MILLION) 87

6.11 OTHER ECLINICAL SOLUTIONS 88

TABLE 42 GLOBAL OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2015–2018 (USD MILLION) 88

TABLE 43 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2018 (USD MILLION) 88

TABLE 44 GLOBAL OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2019–2026 (USD MILLION) 89

TABLE 45 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2019–2026 (USD MILLION) 89

7 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE 90

7.1 INTRODUCTION 91

TABLE 46 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY MODE OF DELIVERY, 2015–2018 (USD MILLION) 91

TABLE 47 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 91

7.2 WEB-HOSTED (ON-DEMAND) SOLUTIONS 91

TABLE 48 WEB-HOSTED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2015–2018 (USD MILLION) 92

TABLE 49 WEB-HOSTED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2019–2026 (USD MILLION) 92

7.3 LICENSED ENTERPRISE (ON-PREMISES) SOLUTIONS 92

TABLE 50 LICENSED ENTERPRISE ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2018 (USD MILLION) 93

TABLE 51 LICENSED ENTERPRISE ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2019–2026 (USD MILLION) 93

7.4 CLOUD-BASED (SAAS) SOLUTIONS 94

TABLE 52 CLOUD-BASED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2015–2018 (USD MILLION) 95

TABLE 53 CLOUD-BASED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2019–2026 (USD MILLION) 95

8 GLOBAL ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE 96

8.1 INTRODUCTION 97

FIGURE 23 PHASE III TRIALS SEGMENT TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 97

TABLE 54 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 97

TABLE 55 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 98

8.2 PHASE I CLINICAL TRIALS 98

TABLE 56 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE I CLINICAL TRIALS,

BY REGION, 2015–2018 (USD MILLION) 98

TABLE 57 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE I CLINICAL TRIALS,

BY REGION, 2019–2026 (USD MILLION) 99

8.3 PHASE II CLINICAL TRIALS 99

TABLE 58 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE II CLINICAL TRIALS,

BY REGION, 2015–2018 (USD MILLION) 100

TABLE 59 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE II CLINICAL TRIALS,

BY REGION, 2019–2026 (USD MILLION) 100

8.4 PHASE III CLINICAL TRIALS 100

TABLE 60 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE III CLINICAL TRIALS,

BY REGION, 2015–2018 (USD MILLION) 101

TABLE 61 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE III CLINICAL TRIALS,

BY REGION, 2019–2026 (USD MILLION) 101

8.5 PHASE IV CLINICAL TRIALS 102

TABLE 62 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE IV CLINICAL TRIALS,

BY REGION, 2015–2018 (USD MILLION) 102

TABLE 63 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE IV CLINICAL TRIALS,

BY REGION, 2019–2026 (USD MILLION) 102

9 ECLINICAL SOLUTIONS MARKET, BY END USER 103

9.1 INTRODUCTION 104

FIGURE 24 GLOBAL ECLINICAL SOLUTIONS MARKET SHARE, BY END USER (2020) 104

TABLE 64 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 104

TABLE 65 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 105

9.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 105

TABLE 66 ECLINICAL SOLUTIONS MARKET SIZE FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2015–2018 (USD MILLION) 106

TABLE 67 ECLINICAL SOLUTIONS MARKET SIZE FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019–2026 (USD MILLION) 106

9.3 CONTRACT RESEARCH ORGANIZATIONS 106

TABLE 68 KEY STRATEGIC ALLIANCES BETWEEN CROS AND PHARMA COMPANIES (2011–2015) 107

TABLE 69 ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY REGION,

2015–2018 (USD MILLION) 107

TABLE 70 ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY REGION,

2019–2026 (USD MILLION) 108

9.4 CONSULTING SERVICE COMPANIES 108

TABLE 71 ECLINICAL SOLUTIONS MARKET SIZE FOR CONSULTING SERVICE COMPANIES, BY REGION, 2015–2018 (USD MILLION) 109

TABLE 72 ECLINICAL SOLUTIONS MARKET SIZE FOR CONSULTING SERVICE COMPANIES, BY REGION, 2019–2026 (USD MILLION) 109

9.5 MEDICAL DEVICE MANUFACTURERS 109

TABLE 73 ECLINICAL SOLUTIONS MARKET SIZE FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2015–2018 (USD MILLION) 110

TABLE 74 ECLINICAL SOLUTIONS MARKET SIZE FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2019–2026 (USD MILLION) 110

9.6 HOSPITALS 110

TABLE 75 ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY REGION,

2015–2018 (USD MILLION) 111

TABLE 76 ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY REGION,

2019–2026 (USD MILLION) 111

9.7 ACADEMIC RESEARCH INSTITUTES 111

TABLE 77 ECLINICAL SOLUTIONS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2015–2018 (USD MILLION) 112

TABLE 78 ECLINICAL SOLUTIONS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 112

10 ECLINICAL SOLUTIONS MARKET, BY REGION 113

10.1 INTRODUCTION 114

FIGURE 25 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2021 VS. 2026 (USD MILLION) 114

TABLE 79 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2015–2018 (USD MILLION) 115

TABLE 80 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY REGION,

2019–2026 (USD MILLION) 115

10.2 NORTH AMERICA 116

FIGURE 26 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SNAPSHOT 116

TABLE 81 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY,

2015–2018 (USD MILLION) 117

TABLE 82 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY,

2019–2026 (USD MILLION) 117

TABLE 83 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 117

TABLE 84 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 118

TABLE 85 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2018 (USD MILLION) 118

TABLE 86 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2019–2026 (USD MILLION) 118

TABLE 87 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 119

TABLE 88 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 119

TABLE 89 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2018 (USD MILLION) 119

TABLE 90 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2019–2026 (USD MILLION) 120

10.2.1 US 120

10.2.1.1 Availability of government funding for clinical research to drive market growth 120

TABLE 91 US: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 121

TABLE 92 US: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 122

TABLE 93 US: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 122

TABLE 94 US: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 122

TABLE 95 US: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE,

2015–2018 (USD MILLION) 123

TABLE 96 US: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE,

2019–2026 (USD MILLION) 123

TABLE 97 US: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 123

TABLE 98 US: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 124

10.2.2 CANADA 124

10.2.2.1 Government support to contribute to market growth 124

TABLE 99 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 125

TABLE 100 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 125

TABLE 101 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 126

TABLE 102 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 126

TABLE 103 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 126

TABLE 104 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 127

TABLE 105 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 127

TABLE 106 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 127

10.3 EUROPE 128

FIGURE 27 EUROPE: ECLINICAL SOLUTIONS MARKET SNAPSHOT 128

TABLE 107 EMA-APPROVED BIOSIMILARS 129

TABLE 108 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY,

2015–2018 (USD MILLION) 132

TABLE 109 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY,

2019–2026 (USD MILLION) 132

TABLE 110 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 133

TABLE 111 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 133

TABLE 112 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 134

TABLE 113 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 134

TABLE 114 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 134

TABLE 115 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 135

TABLE 116 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018(USD MILLION) 135

TABLE 117 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 135

10.3.1 GERMANY 136

10.3.1.1 Increasing R&D investments and initiatives to boost market growth 136

TABLE 118 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 136

TABLE 119 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 137

TABLE 120 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 137

TABLE 121 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 137

TABLE 122 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 138

TABLE 123 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 138

TABLE 124 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018(USD MILLION) 138

TABLE 125 GERMANY: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 139

10.3.2 UK 139

10.3.2.1 Favorable R&D scenario to boost software adoption 139

TABLE 126 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 140

TABLE 127 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 140

TABLE 128 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 141

TABLE 129 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 141

TABLE 130 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE,

2015–2018 (USD MILLION) 141

TABLE 131 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE,

2019–2026 (USD MILLION) 142

TABLE 132 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018(USD MILLION) 142

TABLE 133 UK: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 142

10.3.3 FRANCE 143

10.3.3.1 High number of oncology clinical trials to drive market growth 143

TABLE 134 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 143

TABLE 135 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 144

TABLE 136 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 144

TABLE 137 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 144

TABLE 138 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 145

TABLE 139 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 145

TABLE 140 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018(USD MILLION) 145

TABLE 141 FRANCE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 146

10.3.4 ITALY 146

10.3.4.1 Low drug approval times drive growing adoption of eClinical solutions 146

TABLE 142 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017 146

TABLE 143 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 147

TABLE 144 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 147

TABLE 145 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 148

TABLE 146 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 148

TABLE 147 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 148

TABLE 148 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 149

TABLE 149 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018(USD MILLION) 149

TABLE 150 ITALY: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 149

10.3.5 SPAIN 150

10.3.5.1 Rising R&D expenditure to propel market growth 150

TABLE 151 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 150

TABLE 152 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 151

TABLE 153 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 151

TABLE 154 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 151

TABLE 155 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 152

TABLE 156 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 152

TABLE 157 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018(USD MILLION) 152

TABLE 158 SPAIN: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 153

10.3.6 REST OF EUROPE 153

TABLE 159 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2018 (USD MILLION) 154

TABLE 160 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2019–2026 (USD MILLION) 154

TABLE 161 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2018 (USD MILLION) 155

TABLE 162 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2019–2026 (USD MILLION) 155

TABLE 163 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 155

TABLE 164 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 156

TABLE 165 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2018(USD MILLION) 156

TABLE 166 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2019–2026 (USD MILLION) 156

10.4 ASIA-PACIFIC 157

FIGURE 28 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SNAPSHOT 157

TABLE 167 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY,

2015–2018 (USD MILLION) 159

TABLE 168 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY,

2019–2026 (USD MILLION) 159

TABLE 169 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 160

TABLE 170 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 160

TABLE 171 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2018 (USD MILLION) 161

TABLE 172 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2019–2026 (USD MILLION) 161

TABLE 173 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 161

TABLE 174 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 162

TABLE 175 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 162

TABLE 176 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 162

10.4.1 CHINA 163

10.4.1.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market growth 163

TABLE 177 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 163

TABLE 178 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 164

TABLE 179 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 164

TABLE 180 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 164

TABLE 181 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 165

TABLE 182 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 165

TABLE 183 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 165

TABLE 184 CHINA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 166

10.4.2 JAPAN 166

10.4.2.1 Stringent regulatory scenario to restrain market growth 166

TABLE 185 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 166

TABLE 186 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 167

TABLE 187 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 167

TABLE 188 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 167

TABLE 189 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 168

TABLE 190 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 168

TABLE 191 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 168

TABLE 192 JAPAN: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 169

10.4.3 INDIA 169

10.4.3.1 Favorable pharmaceutical R&D scenario to drive software adoption 169

TABLE 193 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2015–2018 (USD MILLION) 170

TABLE 194 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT,

2019–2026 (USD MILLION) 170

TABLE 195 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2015–2018 (USD MILLION) 171

TABLE 196 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE,

2019–2026 (USD MILLION) 171

TABLE 197 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 171

TABLE 198 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 172

TABLE 199 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2015–2018 (USD MILLION) 172

TABLE 200 INDIA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER,

2019–2026 (USD MILLION) 172

10.4.4 REST OF ASIA PACIFIC 173

TABLE 201 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2018 (USD MILLION) 173

TABLE 202 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2019–2026 (USD MILLION) 173

TABLE 203 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2018 (USD MILLION) 174

TABLE 204 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2019–2026 (USD MILLION) 174

TABLE 205 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 174

TABLE 206 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 175

TABLE 207 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2018 (USD MILLION) 175

TABLE 208 REST OF ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2019–2026 (USD MILLION) 175

10.5 REST OF THE WORLD 176

FIGURE 29 ROW: ECLINICAL SOLUTIONS MARKET SNAPSHOT 176

TABLE 209 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2018 (USD MILLION) 177

TABLE 210 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2019–2026 (USD MILLION) 178

TABLE 211 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2018 (USD MILLION) 178

TABLE 212 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2019–2026 (USD MILLION) 178

TABLE 213 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2018 (USD MILLION) 179

TABLE 214 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2019–2026 (USD MILLION) 179

TABLE 215 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2018 (USD MILLION) 179

TABLE 216 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2019–2026 (USD MILLION) 180

11 COMPETITIVE LANDSCAPE 181

11.1 INTRODUCTION 181

11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 181

FIGURE 30 ECLINICAL SOLUTIONS MARKET: STRATEGIES ADOPTED 181

11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 182

FIGURE 31 KEY PLAYERS IN ECLINICAL SOLUTIONS MARKET 182

11.4 MARKET SHARE ANALYSIS 183

FIGURE 32 GLOBAL ECLINICAL SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2020 183

11.5 COMPANY EVALUATION QUADRANT 183

11.5.1 STARS 184

11.5.2 EMERGING LEADERS 184

11.5.3 PERVASIVE PLAYERS 184

11.5.4 PARTICIPANTS 184

FIGURE 33 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT, 2020 185

11.6 ECLINICAL SOLUTIONS MARKET: SME EVALUATION 186

11.6.1 PROGRESSIVE COMPANIES 186

11.6.2 STARTING BLOCKS 186

11.6.3 RESPONSIVE COMPANIES 186

11.6.4 DYNAMIC COMPANIES 186

FIGURE 34 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT FOR SMES, 2020 187

11.7 COMPETITIVE BENCHMARKING 188

11.7.1 COMPANY SERVICE FOOTPRINT (25 COMPANIES) 188

FIGURE 35 COMPANY PORTFOLIO FOOTPRINT: ECLINICAL SOLUTIONS MARKET 188

TABLE 217 COMPANY REGION FOOTPRINT (25 COMPANIES) 189

11.8 COMPETITIVE SITUATIONS AND TRENDS 190

11.8.1 PRODUCT/SERVICE LAUNCHES 190

TABLE 218 PRODUCT/SERVICE LAUNCHES (2018 TO 2021) 190

11.8.2 DEALS 191

TABLE 219 DEALS 191

TABLE 220 OTHER DEVELOPMENTS 194

12 COMPANY PROFILES 195

(Business Overview, Products & services Offered, Recent Developments, and Right to win)*

12.1 KEY PLAYERS 195

12.1.1 ORACLE CORPORATION. 195

TABLE 221 ORACLE CORPORATION: BUSINESS OVERVIEW 195

FIGURE 36 ORACLE CORPORATION: COMPANY SNAPSHOT (2020) 196

12.1.2 DASSAULT SYSTÈMES 199

TABLE 222 DASSAULT SYSTÈMES: BUSINESS OVERVIEW 199

FIGURE 37 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2020) 200

12.1.3 PAREXEL INTERNATIONAL CORPORATION 204

TABLE 223 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 204

12.1.4 BIOCLINICA, INC. (SUBSIDIARY OF CINVEN) 206

TABLE 224 BIOCLINICA : BUSINESS OVERVIEW 206

12.1.5 DATATRAK INTERNATIONAL, INC. 209

TABLE 225 DATATRAK INTERNATIONAL, INC: BUSINESS OVERVIEW 209

FIGURE 38 DATATRAK INTERNATIONAL, INC.: COMPANY SNAPSHOT (2020) 209

12.1.6 SIGNANT HEALTH (CRF HEALTH) 211

TABLE 226 SIGNANT HEALTH : BUSINESS OVERVIEW 211

12.1.7 ERT CLINICAL 213

TABLE 227 NELSON LABORATORIES: BUSINESS OVERVIEW 213

12.1.8 MAXISIT INC. 216

TABLE 228 MAXISIT INC.: BUSINESS OVERVIEW 216

12.2 OTHER PLAYERS 218

12.2.1 4G CLINICAL 218

12.2.2 ECLINICAL SOLUTIONS LLC 218

12.2.3 VEEVA SYSTEMS 219

12.2.4 RESEARCH MANAGER 219

12.2.5 SAAMA TECHNOLOGIES 220

12.2.6 MEDNET 220

12.2.7 ANJU SOFTWARE (PORTFOLIO COMPANY OF ABRY PARTNERS) 221

12.2.8 MEDRIO INC 221

12.2.9 CASTOR EDC 222

12.2.10 CLINPACE CLINICAL RESEARCH 222

12.2.11 IBM WATSON HEALTH 223

12.2.12 ARIS GLOBAL 223

12.2.13 QURETEC. LTD 224

12.2.14 OPENCLINICA 224

12.2.15 ADVARRA 225

12.2.16 REAL TIME SOFTWARE SOLUTIONS 226

12.2.17 YPRIME 226

*Details on Business Overview, Products & services Offered, Recent Developments, and Right to win might not be captured in case of unlisted companies.

13 APPENDIX 227

13.1 DISCUSSION GUIDE* 227

13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 231

13.3 AVAILABLE CUSTOMIZATIONS 233

13.4 RELATED REPORTS 233

13.5 AUTHOR DETAILS 234

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（end user）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（end user）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?